Clinical trial
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Effect of VIA-2291, a 5-Lipoxygenase Inhibitor, on Vascular Inflammation in Patients After an Acute Coronary Syndrome Event
NCT00552188 is registered in ClinicalTrials.gov with Tallikut Pharmaceuticals, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Effect of VIA-2291, a 5-Lipoxygenase Inhibitor, on Vascular Inflammation in Patients After an Acute Coronary Syndrome Event
- Lead sponsor
- Tallikut Pharmaceuticals, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- October 31, 2007
- Completion date
- November 30, 2009
- Enrollment
- 52 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.